



Investor service announcement no. 2/2016

Hørsholm, Denmark, 9 March, 2016

### **Veloxis Pharmaceuticals A/S moves Danish activities to the U.S.**

Veloxis Pharmaceuticals A/S ("Veloxis") has decided to close its office in Hørsholm, Denmark, and move all activities to the U.S. where most of the company's current activities is already located. The process is expected to be completed during the second half of 2016.

"As most of the company's activities are located in the U.S. combined with the launch of Envarsus® XR in the US through our own sales force we believe a consolidation of activities will further strengthen the company to meet new opportunities and to further grow our business." said Craig Collard, CEO.

Veloxis will continue to be a Danish company listed on Nasdaq Copenhagen A/S.

The information provided in this announcement does not change Veloxis' financial guidance for the 2015 financial year.

#### **For more information, please contact:**

Craig A. Collard  
President & CEO  
Phone: +1 919 524 4317  
Email: cac@veloxis.com

#### **Veloxis Pharmaceuticals A/S (VELO)**

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit [www.veloxis.com](http://www.veloxis.com).